Valeant Pharmaceuticals International, Inc. (Sanofi)

The FTC approved consent orders requiring Valeant Pharmaceuticals International to divest three dermatological drug products as a condition of acquiring Ortho Dermatologics and Dermik Laboratories. Valeant was required to sell manufacturing and marketing rights for acne and actinic keratosis treatments to Mylan Pharmaceuticals, and marketing rights for a fine-line wrinkle treatment to Spear Pharmaceuticals. The settlements were designed to preserve competition and prevent price increases that would have resulted from the acquisitions. No marketing claims were flagged; this is a merger-remedy consent order.